New Hematology Treatments for Essential Thrombocythemia and Polycythemia Vera

On August 31, FDA expanded BESReMi for essential thrombocythemia and approved weekly rusfertide (Mimrylo) for polycythemia vera, broadening treatment options for chronic myeloproliferative neoplasms. Interferon-related safety and monitoring, comparative efficacy, sequencing, and real-world thrombotic benefit will determine their clinical positioning.